Abstract
Purpose
The purpose of this study is to discuss the clinical presentation, management, and outcomes of patients with primary orbital Ewing sarcoma family of tumors (ESFTs).
Patients and methods
Retrospective study of 12 patients with biopsy-proven primary orbital ESFT.
Results
The mean age at presentation of primary orbital ESFT was 12 years (median, 8 years; range, 5 months to 28 years). There were seven (58%) females and five (42%) males. The presenting complaints included proptosis (n=10; 83%) and swelling in the upper eyelid (n=2; 17%). The mean duration of symptoms was 9 weeks (median, 5 weeks; range, 2–24 weeks). Tumor epicenter was located in the superior orbit (n=6; 50%), lateral orbit (n=3; 25%), inferior orbit (n=2; 17%), and medial orbit (n=1; 8%). Computed tomography of the orbits revealed predominant bony lesion (n=10; 83%) or isolated soft tissue/extraosseous lesion (n=2, 17%). At presentation, extraorbital extension was noticed in 10 patients including intra cranial extension (n=7; 58%), extension into temporal fossa (n=4; 33%), nasal cavity (n=2; 17%), maxillary sinus (n=2; 17%), and ethmoid sinus (n=1, 8%). Systemic metastases at presentation was detected in five (42%) patients involving the bone marrow (n=4; 33%), kidney (n=1; 8%), and retroperitoneal lymphnode (n=1; 8%). Multi-modal treatment including a combination of neoadjuvant chemotherapy, excision biopsy/debulking, and/or radiotherapy was given. Over a mean follow-up period of 21 months (median, 7 months; range, 1–152 months), disease-related death occurred in 11 (92%) cases.
Conclusion
Primary orbital ESFT is aggressive at presentation and is associated with poor prognosis.
Similar content being viewed by others
Introduction
Ewing sarcoma family of tumors (ESFTs) are malignant tumors of neuroectodermal origin, arising within the bone or soft tissue. ESFT encompasses Ewing sarcoma of the bone (ESB), extraosseous Ewing sarcoma (EES), peripheral primitive neuroectodermal tumor (pPNET) of the bone, and Askin’s tumor of the chest wall.1 Classical Ewing sarcoma (ESB and EES) displays minimal evidence of neural differentitation and pPNET is characterized by neural differentiation by standard microscopy, electron microscopy, or immunohistochemistry.1 These tumors are characterized by similar morphological features of small round blue cell tumors, immunohistochemical features of expression of membrane CD99 protein, cytogenetic features of t(11;22) translocation or t(21;22) rearrangement, and molecular features of hybrid transcripts of the EWS gene with the FLI1 or ERG gene.1, 2
In a study of 856 cases of ESFT, the tumor site included lower extremity (35%), chest (21%), pelvis (17%), spine (10%), upper extremity (9%), head and neck (6%), and abdomen (2%).3 Primary orbital ESFT is extremely rare with isolated case reports and small case series reported in literature.4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 Herein we discuss the demographic profile, clinical features, radiological features, treatment modalities, and outcomes of primary orbital ESFTs.
Methods
Institutional review board approval was obtained for the study. A database search was conducted for the diagnosis of ‘Ewing sarcoma orbit’ managed at the Operation Eyesight Universal Institute for Eye Cancer, LV Prasad Eye Institute, Hyderabad, from January 1996 to October 2016. Inclusion criteria were histopathologically confirmed cases of primary ESFT. Those with inadequate data or with orbital metastasis of Ewing sarcoma from elsewhere were excluded.
Medical records were analysed for age at presentation, gender, laterality, symptoms, duration of symptoms, clinical features, radiological features, treatment, histopathological features, and outcome. Computed tomography (CT) images of the orbit were reviewed from the photography archives. The tumor epicenter, predominant osseous or extraosseous component, and extent of the lesion were noted. All patients were examined by the medical oncologist at initial presentation and systemic work-up (bone marrow biopsy, contrast enhanced CT chest, ultrasound/CT abdomen, and bone scan) was done.
All patients underwent incision biopsy/debulking of the lesion to confirm the diagnosis of ESFT. The lesions with indistinct neural differentiation on histopathology with predominant osseous lesion clinicoradiologically were classified as ESB and those with exclusive extraosseous component clinicoradiologically were classified as EES. The tumors with evidence of neural differentiation and rosettes/pseudorosettes were classified as pPNET. After the histopathology confirmation of the diagnosis, the treatment was initiated. The treatment protocol included four to five cycles of neoadjuvant chemotherapy with vincristine, adriamycin, and cyclophosphamide alternating with etoposide and ifosfamide, local therapy of surgical excision/debulking, and/or radiotherapy followed by continuation of chemotherapy with similar agents, to complete a duration of 49 weeks.
Follow-up was done every 3 weeks during chemotherapy and every 3 months thereafter for the next 1 year, and every 6 months thereafter. A detailed systemic evaluation was done at each follow-up visit by the medical oncologist. Any event of metastasis or death was noted.
Results
Fourteen cases with orbital ESFTs were identified during the study period. One patient was initially diagnosed with primary orbital ESFTs but on further evaluation, was detected to have the primary site of origin at right tibia with secondary orbital involvement. Another patient was a diagnosed case of ESFT of the left tibia with spinal metastasis and presented to us with secondary orbital involvement. Both these patients with secondary orbital involvement were excluded from the study.
A total of 12 cases met the inclusion criteria (Table 1). The mean age at presentation was 12 years (median, 8 years; range, 5 months to 28 years). Seven (58%) of the 12 patients were younger than 10 years of age. There were seven (58%) females and five (42%) males. All of them had unilateral disease with the left eye being involved in 10 (83%) and right in 2 (17%). The presenting complaints included proptosis (n=10; 83%) and swelling in the upper eyelid (n=2; 17%). The mean duration of symptoms was 9 weeks (median, 5 weeks; range, 2–24 weeks). Tumor epicenter was located in the superior orbit (n=6; 50%), lateral orbit (n=3; 25%), inferior orbit (n=2; 17%), and medial orbit (n=1; 8%). Regional lymphadenopathy was present in two patients including submandibular lymph nodes (n=1, 17%) and upper deep cervical lymph nodes (n= 1; 17%).
CT orbits (Figure 1) revealed predominant osseous lesion in 10 (83%) patients, whereas 2 (17%) patients presented with isolated soft tissue/extraosseous lesion without signs of bone erosion/ destruction. At presentation, extraorbital extension was noted in 10 (87%) patients including intra cranial extension (n=7; 58%), extension into the temporal fossa (n=4; 33%), nasal cavity (n=2; 17%), maxillary sinus (n=2; 17%), and ethmoid sinus (n=1, 8%). Among the 12 patients, systemic metastases at presentation were detected in 5 (42%) patients involving the bone marrow (n=4; 33%), kidney (n=1; 8%), and retroperitoneal lymphnode (n=1; 8%). No extraorbital extension or systemic metastasis was detected in the two patients with extraosseous ESFTs.
Ten patients with locoregional tumor extension underwent incision biopsy from the lesion for histopathological diagnosis and two patients with isolated well-defined extraosseous lesion underwent tumor debulking/excision biopsy. Light microscopic examination revealed sheets of small, round, uniform cells with scant clear cytoplasm, indistinct cell membranes, round nuclei with indentations, and small nucleoli. Homer–Wright rosettes or pseudorosettes were present in three (25%) patients. Immunohistochemistry demonstrated CD 99/ MIC-2 positivity in all the patients confirming the diagnosis of ESFTs. Based on clinicoradiological features, histopathology, and immunohistochemistry, the final diagnosis was made as ESB in seven (58%), EES in two (17%), and pPNET in three (25%) patients. Systemic chemotherapy was given to all patients and only six patients received adjuvant external beam radiotherapy of 50 Gy to the orbit, as six patients died while on chemotherapy early in the follow-up before the commencement of radiotherapy.
Over a mean follow-up period of 21 months (median, 7 months; range, 1–152 months), disease-related death occurred in 11 (92%) cases. Among the 11 patients who died, the mean survival time was 10 months (median, 7 months; range, 1–30 months).
Four (33%) patients survived for <6 months after diagnosis of ESFTs. At presentation, all these patients were >5 years of age at presentation, had predominant osseous lesion with intracranial tumor extension, and systemic metastasis at presentation (bone marrow metastasis=1; renal metastasis=1). At the time of this manuscript preparation, only one patient was alive. This patient presented at 5 months of age with ESB with tumor extension into the maxillary sinus but with no evidence of metastasis at presentation or during the follow-up period. The patient responded well to treatment and is disease free at 12 years of follow-up.
Discussion
ESFT is a highly malignant tumor of the bone and soft tissue and is most commonly seen in children and young adults under the age of 20 years.1 The mean age at presentation in males is 10–14 years and in females is 5–9 years.1 In our series, 9 (75%) patients were ≤20 years at presentation and the mean age at presentation was 13 years in females and 11 years in males.
ESFTs most commonly involves the central axis including pelvis (17–20%) and chest (20–21%).1, 3 ESFTs involving head and neck is seen in only 3–9% cases.1, 3, 22 In an analysis of large series of 183 cases of head and neck ESFTs, orbit involvement was evident in only 3 (2%) cases, suggestive of its rarity.23 There are only 41 cases of primary orbital ESFTs published in the literature.4, 24 Based on the available data, the mean age at presentation of these published cases was 7 years (median, 7 years; range, 0.5–20 years).4, 24 In our series, the mean age at presentation was higher at 12 years, whereas the median age at presentation was comparable at 8 years.
Of all ESFTs, osseous lesions with/without soft tissue component (85%) are more common compared with soft tissue/extraosseous lesions (15%).3 ESB most commonly involves upper or lower extremity (44–52%).1, 3 EES commonly involves extremities (26%), head and neck (18%), and retroperitoneum (16%).25 pPNET commonly involves chest (44%), pelvis and abdomen (26%), extremities (20%), and head and neck (6%).1 ESFTs of head and neck commonly involves bones of the skull and face, including mandible in 49% and soft tissues of head and neck in 30% cases.23 In our series of primary orbital ESFTs, an osseous lesion was noted in 10 (83%) and soft tissue/extraosseous lesion in 2 (17%) cases. Based on histopathology, immunohistochemistry, and clinicoradiological features, the lesions were classified as ESB in seven (58%), EES in two (17%), and pPNET in three (25%) patients.
Ewing sarcoma has a better prognosis than pPNET. Schmidt et al26 studied 81 cases of Ewing sarcoma and 36 cases of pPNET, and reported a disease-free survival rate of 60% in Ewing sarcoma and 45% in pPNET patients at 7.5 years follow-up. However, this study included ESFTs at any site but not limited to the orbit. In our study of primary orbital ESFTs, only one patient survived over a mean follow-up period of 21 months and this patient had ESB. All patients with pPNET died within 2 years of diagnosis.
Histopathologically, ESFTs are composed of small, round, hyperchromatic cells with varying degrees of neural differentiation. Differential diagnosis of small round cell tumors include ESFT, neuroblastoma, rhabdomyosarcoma, lymphoma, osteogenic sarcoma, and mesenchymal chondrosarcoma.4, 27 Immunohistochemical and/or ultrastructural techniques are useful to establish the diagnosis. Immunostaining with CD99 is the keystone in the diagnosis and is a common feature of ESFTs.4 In our study, CD99 was positive in all cases. Fluorescence in situ hybridization studies to detect chromosome (11;22) translocation can also be used for definite diagnosis of ESFTs.4
ESFTs exhibits rapid progression and have poor prognosis. Local tumor extension and clinical metastases are often found during initial diagnosis of ESFTs. Overt metastatic disease is evident in 20–25% cases.1 It is assumed that most patients with ESFTs have a subclinical metastatic disease at presentation due to its association with high relapse rate in patients treated with only local treatment without systemic chemotherapy. In patients with no clinically detectable metastatic disease, bone marrow micrometastases has been detected by reverse transcription-polymerase chain reaction in 20–30% patients.1, 28, 29 In our series, local tumor extension was evident in 10 (83%) and overt metastasis at presentation in 5 (42%) cases.
The current treatment strategy for ESFTs is combined neoadjuvant chemotherapy with surgical resection or radiotherapy followed by adjuvant chemotherapy.1 The treatment plan consists of three stages, which includes initial cytoreduction with chemotherapy to eradicate micro metastatic disease and facilitate effective local tumor control measures, definitive radiation or surgical therapy to eradicate all known disease, and consolidation therapy for eradication of occult residual disease to reduce the likelihood of tumor recurrence. Multiagent chemotherapeutic protocols using doxorubicin, cyclophosphamide, vincristine, dactinomycin, ifosfamide, etoposide, topotecan, irinotecan, and cisplatin have been used in various clinical trials.1, 3, 30, 31, 32 Alternating courses of vincristine, doxorubicin, and cyclophosphomide, with ifosfamide and etoposide, are most commonly used, similar to our series. There are no proven benefits of bone marrow transplantation, stem cell transplantation, and targeted therapy. The treatment of metastatic disease is similar to localized ESFTs with multimodal treatment; however, the cure rate is poor.33, 34 In an analysis of 975 patients with ESFTs, it was noted that the 5-year relapse-free survival in patients with no metastasis at presentation was 55 versus 22% for patients with metastasis at presentation.35
The poor prognostic factors for ESFTs are metastatic disease at presentation, large tumor >5 cm, older age, male gender, central tumor location including skull, clavicle, ribs, pelvis, vertebrae, and the upper extremities.35, 36, 37, 38 Orbital ESFT is considered to be less aggressive than ESFT at other locations in the body,4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 39 as the survival has been more than 6 months in majority of the reported cases. Although extraorbital extension is frequently reported with primary orbital ESFTs, systemic metastases at presentation or during follow-up duration is rare as per the available literature.4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 39 However, in our series, systemic metastases was detected in five (42%) patients at presentation and the most common site of metastasis was the bone marrow (33%). Of the reported 41 cases in the literature, disease-related mortality was noted in 9 (22%) patients over a mean follow-up period of 27 months (median, 17 months; range, 3–84 months).4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 39 However, in our series, disease-related mortality was noted in 11 (92%) patients over a mean follow-up period of 21 months (median, 7 months; range, 1–152 months) despite using a standard treatment protocol. The high rate of mortality in our series could be attributed to referral bias or advanced disease including intracranial extension (n=7), and/or systemic metastasis (n=5) at presentation. In our series, all patients with systemic metastasis at presentation died due to the disease before completion of treatment.
In our series, complete surgical debulking could not be achieved in cases (n=10) with extensive locoregional involvement of the tumor. Of these 10 patients, only 1 patient survived following subsequent systemic chemotherapy and orbital radiotherapy. Only two patients with isolated well-defined extraosseous lesions underwent complete surgical debulking/excision biopsy, but both died due to the disease in less than one year. As this is a retrospective study, it is difficult to predict whether complete/near-total surgical debulking in cases with extensive locoregional tumor could influence the final outcome. However, it should be noted that, in cases with extenive orbital disease with tumor extension into paranasal sinuses, brain, and surrounding vital structures, complete tumor resection remains a challenge. Combination of systemic chemotherapy and radiotherapy may be an effective alternative to surgical resection in selected cases for local tumor control, where surgical resection results in significant cosmetic mutilation and/or physical handicap.21, 40 However, a combination of surgical resection, chemotherapy, and radiotherapy is associated with better locoregional control and survival rate compared with those without surgical resection.40
In a study of 1039 localized ESFT patients who underwent treatment, the 5-year overall event-free survival estimate for extraosseous ESFTs was 76% compared with 69% for patients with osseous ESFTs.41 However, patients with systemic metastasis at presentation have a poor prognosis with survival rate of only 20%.42 In our study, seven patients had intracranial extension and five had systemic metastasis at presentation, and all of them died due to the disease. The only patient who survived had an osseous lesion with no evidence of intracranial extension or systemic metastasis at presentation.
In summary, primary ESFTs of the orbit is a rare tumor, which poses a diagnostic challenge and demands a very high index of suspicion. Older age at presentation (>1 year), intracranial tumor extension, and systemic metastasis at presentation are poor prognostic features in primary orbital ESFTs.
References
Carvajal R, Meyers P . Ewing's sarcoma and primitive neuroectodermal family of tumors. Hematol Oncol Clin North Am 2005; 19 (3): 501–525.
Delattre O, Zucman J, Melot T, Garau XS, Zucker JM, Lenoir GM et al. The Ewing family of tumors: a subgroup of small-round cell tumors defined by specific chimeric transcripts. N Engl J Med 1994; 331: 294–299.
Le Deley MC, Paulussen M, Lewis I, Brennan B, Ranft A, Whelan J et al. Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial. J Clin Oncol 2014; 32 (23): 2440–2448.
Alfaar AS, Zamzam M, Abdalla B, Magdi R, El-Kinaai N . Childhood Ewing sarcoma of the orbit. J Pediatr Hematol Oncol 2015; 37 (6): 433–437.
Klufas MA, Wolden SL, Bohle GC 3rd, Wexler LH, Abramson DH . Exenteration and custom implant brachytherapy as a treatment for recurrent primary extraskeletal orbital Ewing sarcoma. Ophthal Plast Reconstr Surg 2015; 31 (4): e89–e91.
Naqvi SH, Hameed S, Naqvi SH, Musani MA . Primary Ewing's sarcoma of the orbit with intracranial extension abutting the temporal lobe: a rare case report. Int Ophthalmol 2014; 34 (5): 1137–1140.
Alio JL 2nd, Sales-Sanz M, Vaz MA, Barrancos C, Reguero ME, Diamantopoulus J et al. Primary extraosseous Ewing sarcoma of the orbit. Ophthal Plast Reconstr Surg 2013; 29 (3): e91–e93.
Nair AP, Bettaswamy G, Jaiswal AK, Garg P, Jaiswal S, Behari S . Ewing's sarcoma of the orbit with intracranial extension: a rare cause of unilateral proptosis. J Pediatr Neurosci 2011; 6 (1): 36–39.
Yang Y, Liu Y, Yin Z . Primary orbital Ewing sarcoma. J Pediatr Ophthalmol Strabismus 2011; 48: Online e43–e48.
Chokthaweesak W, Annunziata CC, Alsheikh O, Ng JD, Wilson DJ, Mansoor A et al. Primitive neuroectodermal tumor of the orbit in adults: a case series. Ophthal Plast Reconstr Surg 2011; 27 (3): 173–179.
Kano T, Sasaki A, Tomizawa S, Shibasaki T, Tamura M, Ohye C . Primary Ewing's sarcoma of the orbit: case report. Brain Tumor Pathol 2009; 26 (2): 95–100.
Pang NK, Bartley GB, Giannini C . Primary Ewing sarcoma of the orbit in an adult. Ophthal Plast Reconstr Surg 2007; 23 (2): 153–154.
Guzowski M, Tumuluri K, Walker DM, Maloof A . Primary orbital Ewing sarcoma in a middle-aged man. Ophthal Plast Reconstr Surg 2005; 21 (6): 449–451.
Li T, Goldberg RA, Becker B, McCann J . Primary orbital extraskeletal ewing sarcoma. Arch Ophthalmol 2003; 121 (7): 1049–1052.
Bajaj MS, Pushker N, Sen S, Chandra M, Ghose S, Shekar CN . Primary Ewing's sarcoma of the orbit: a rare presentation. J Pediatr Ophthalmol Strabismus 2003; 40 (2): 101–104.
Wilson DJ, Dailey RA, Griffeth MT, Newton CJ . Primary Ewing sarcoma of the orbit. Ophthal Plast Reconstr Surg 2001; 17 (4): 300–303.
Dutton JJ, Rose JG Jr, DeBacker CM, Gayre G . Orbital Ewing's sarcoma of the orbit. Ophthal Plast Reconstr Surg 2000; 16 (4): 292–300.
Tewari MK, Sharma BS, Banerjee AK, Mathuriya SN, Kak VK . Primary Ewing's sarcoma of the orbit. Indian Pediatr 1993; 30 (7): 930–933.
Woodruff G, Thorner P, Skarf B . Primary Ewing's sarcoma of the orbit presenting with visual loss. Br J Ophthalmol 1988; 72 (10): 786–792.
Harbert F, Tabor GL Jr . Ewing's tumor of the orbit; report of 2 cases. Am J Ophthalmol 1950; 33 (8): 1219–1225.
Lam DS, Li CK, Cheng LL, Teo JG, Chik KW, Kwan WH et al. Primary orbital Ewing's sarcoma: report of a case and review of the literature. Eye (Lond) 1999; 13: 38–42.
Choi RY, Lucarelli MJ, Imesch PD, Hafez GR, Albert DM, Dortzbach RK . Primary orbital Ewing sarcoma in a middle-aged woman. Arch Ophthalmol 1999; 117 (4): 535–537.
Ellis MA, Gerry DR, Neskey DM, Lentsch EJ . Ewing sarcoma of the head and neck. Ann Otol Rhinol Laryngol 2017; 126 (3): 179–184.
Biswas B, Bakhshi S, Sengupta M . Childhood Ewing sarcoma of orbit: is it so fatal? J Pediatr Hematol Oncol 2016; 38 (1): 82–83.
Kennedy JG, Eustace S, Caufield R, Fennelly DJ, Hurson B, O'Rourke KS . Extraskeletal Ewing’s sarcoma: a case report and review of the literature. Spine 2000; 25: 1996–1999.
Schmidt D, Herrmann C, Jürgens H, Harms D . Malignant peripheral neuroectodermal tumor and its necessary distinction from Ewing’s sarcoma. A report from the Kiel Pediatric Tumor Registry. Cancer 1991; 68 (10): 2251–2259.
Choi EY, Gardner JM, Lucas DR, McHugh JB, Patel RM . Ewing sarcoma. Semin Diagn Pathol 2014; 31 (1): 39–47.
Zoubek A, Ladenstein R, Windhager R, Amann G, Fischmeister G, Kager L et al. Predictive potential of testing for bone marrow involvement in Ewing tumor patients by RT-PCR: a preliminary evaluation. Int J Cancer 1998; 79: 56–60.
Fagnou C, Michon J, Peter M, Bernoux A, Oberlin O, Zucker JM et al. Presence of tumor cells in bone marrow but not in blood is associated with adverse prognosis in patients with Ewing’s tumor. J Clin Oncol 1998; 16: 1707–1711.
Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003; 348 (8): 694–701.
Kolb EA, Kushner BH, Gorlick R, Laverdiere C, Healey JH, LaQuaglia MP et al. Long-term event-free survival after intensive chemotherapy for Ewing’s family of tumors in children and young adults. J Clin Oncol 2003; 21 (18): 3423–3430.
Nesbit ME Jr, Gehan EA, Burgert EO Jr, Vietti TJ, Cangir A, Tefft M et al. Multimodal therapy for the management of primary, nonmetastatic Ewing’s sarcoma of bone: a long-term follow-up of the first intergroup study. J Clin Oncol 1990; 8 (10): 1664–1674.
Cangir A, Vietti TJ, Gehan EA, Burgert EO Jr, Thomas P, Tefft M et al. Ewing’s sarcoma metastatic at diagnosis. Results and comparisons of two Intergroup Ewing’s Sarcoma Studies. Cancer 1990; 66 (5): 887–893.
Paulussen M, Ahrens S, Burdach S, Craft A, Dockhorn-Dworniczak B, Dunst J et al. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol 1998; 9 (3): 275–281.
Cotterill SJ, Ahrens S, Paulussen M, Jürgens HF, Voûte PA, Gadner H et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 2000; 18 (17): 3108–3114.
Shankar AG, Pinkerton CR, Atra A . Local therapy and other factors influencing site of relapse in patients with localised Ewing’s sarcoma. United Kingdom Children’s Cancer Study Group (UKCCSG). Eur J Cancer 1999; 35 (12): 1698–1704.
Donaldson SS, Torrey M, Link MP, Glicksman A, Gilula L, Laurie F et al. A multidisciplinary study investigating radiotherapy in Ewing’s sarcoma: end results of POG #8346. Int J Radiat Oncol Biol Phys 1998; 42 (1): 125–135.
Kushner BH, Hajdu SI, Gulati SC, Erlandson RA, Exelby PR, Lieberman PH . Extracranial primitive neuroectodermal tumors. The Memorial Sloan-Kettering Cancer Center experience. Cancer 1991; 67 (7): 1825–1829.
Romero R, Castano A, Abelairas J, Peralta J, Garcia-Cabezas MA, Sanchez-Orgaz M et al. Peripheral primitive neuroectodermal tumour of the orbit. Br J Ophthalmol 2011; 95 (7): 915–920.
Li M, Hoschar AP, Budd GT, Chao ST, Scharpf J . Primary Ewing's sarcoma of the ethmoid sinus with intracranial and orbital extension: case report and literature review. Am J Otolaryngol 2013; 34 (5): 563–568.
Cash T, McIlvaine E, Krailo MD, Lessnick SL, Lawlor ER, Laack N et al. Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer 2016; 63 (10): 1771–1779.
Iwamoto Y . Diagnosis and treatment of Ewing's sarcoma. Jpn J Clin Oncol 2007; 37 (2): 79–89.
Acknowledgements
This study was supported by The Operation Eyesight Universal Institute for Eye Cancer (SK) and Hyderabad Eye Research Foundation (SK), Hyderabad, India.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Kaliki, S., Rathi, S. & Palkonda, V. Primary orbital Ewing sarcoma family of tumors: a study of 12 cases. Eye 32, 615–621 (2018). https://doi.org/10.1038/eye.2017.278
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/eye.2017.278
This article is cited by
-
Infantile intraorbital Ewing’s sarcoma: case report and review of the literature
Child's Nervous System (2021)
-
The journey of multifunctional bone scaffolds fabricated from traditional toward modern techniques
Bio-Design and Manufacturing (2020)